Skip to content

Search

Prevalence of rheumatic heart disease in young adults from New Caledonia

The prevalence of echocardiographically diagnosed RHD in adults in New Caledonia is estimated at 5.9 per 1000

Susceptibility to acute rheumatic fever based on differential expression of genes involved in cytotoxicity, chemotaxis, and apoptosis

Differences in the immune response, detectable by gene expression, between individuals who are susceptible to ARF and those who are not

Echocardiographic screening in a resource poor setting: Borderline rheumatic heart disease could be a normal variant

Cross-sectional observational study across ten primary schools in Fiji in school children aged 5-14 years.

Echocardiographic screening for rheumatic heart disease in high and low risk Australian children

We aimed to establish the prevalence of RHD in high-risk Indigenous Australian children using these criteria and to compare the findings with a group of...

Benzathine penicillin G for the management of RHD: Concerns about quality and access, and opportunities for intervention and improvement

Benzathine penicillin G is an important antibiotic for the treatment and prevention of group A streptococcal infections associated with rheumatic fever and...

A conceptual framework for comprehensive rheumatic heart disease control programs

The World Health Organization, World Heart Federation, and other organizations recommend comprehensive control programs for rheumatic fever (RF) and...

Prevention of rheumatic fever and heart disease: Nepalese experience

Historically, many young people suffered severe valvular disease and died awaiting heart valve replacement.

Continued challenge of rheumatic heart disease: The gap of understanding or the gap of implementation?

We still do not have a RF vaccine, although the recent announcement that the Australian and New Zealand governments are jointly sponsoring a program to fast...

Rheumatic Heart Disease Control Programs, Registers, and Access to Care

This chapter outlines the evidence and evolution of RHD control programs and draws conclusions about priorities following the 2018 World Health Organization Global Resolution on rheumatic fever and RHD.

Quality of benzathine penicillin G: A multinational cross-sectional study

Benzathine penicillin G (BPG) is used as first-line treatment for most forms of syphilis and as secondary prophylaxis against rheumatic heart disease (RHD). Perceptions that poor quality of BPG is linked to reported adverse effects and therapeutic failure may impact syphilis and RHD control programs. Clinical networks and web-based advertising were used to obtain vials of BPG from a wide range of countries.